Advertisement

Potential Labeling of Monoclonal Antibodies with Positron Emitters

  • Michael J. Welch
  • Michael R. Kilbourn
Conference paper
Part of the NATO ASI Series book series (NSSA, volume 152)

Abstract

The use of gamma-emitting radiolabeled antibodies as diagnostic imaging agents had produced promising results. Positron emission tomography has advantages in areas of resolution, quantification, and sensitivity over conventional γ-imaging. There are two approaches to labeling antibodies with positron-emitting nuclides. In one approach, a long-lived radionuclide such as zirconium-89 (half-life 78 hr) has been suggested as a label for monoclonal antibodies (1). Bromine-76 (2), which has been used to label ligands for the dopamine receptor, could also be used and techniques developed for labeling proteins (3–5) with bromine-77 adapted to this application. Table 1 gives some relevant nuclear data concerning these and other potentially useful positron-emitting radionuclides. Although there are other candidate positron-emitting radionuclides, the ones listed in Table 1 can be used using currently available labeling technology.

Keywords

Progressive Supranuclear Palsy Label Antibody Parathyroid Tissue Phenacyl Bromide Tetrabutylammonium Hydroxide 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    S. F. Eary, J. M. Link, R. Kishore, M. W. Johnson, C. C. Badger, K. Y. Richter, K. A. Krohn, and W. B. Nelp, Production of positron emitting Zr-89 for antibody imaging by PET, J. Nucl. Med. 27:983 (1986).Google Scholar
  2. 2.
    J. C. Baron, B. Maziere, C. Loc’h, H. Cambon, P. Sgouropoulos, A. M. Bonnet, Y. Agid, Loss of striatal [Br-76] bromospiperone binding sites demonstrated by positron tomography in progressive supranuclear palsy, J. Cerebral Blood Flow Metab. 6:131–136 (1986).CrossRefGoogle Scholar
  3. 3.
    L. C. Knight, K. A. Krohn, M. J. Welch, B. Spomer, L. P. Hager, Br-77: A new protein label, in: “Radiopharmaceuticals,” G. Subramanian, B. A. Rhodes, J. F. Cooper, V. J. Sodd, eds., Soc. Nucl. Med., New York, p. 149 (1975).Google Scholar
  4. 4.
    K. D. McElvany, J. W. Barnes, and M. J. Welch, Characterization of bromine-77 labeled proteins using bromoperoxidase, Int. J. Appl. Rad. Isotop. 31:679–688 (1980).CrossRefGoogle Scholar
  5. 5.
    K. D. McElvany, and M. J. Welch, Characterization of bromine-77-labeled proteins prepared using bromoperoxidase, J. Nucl. Med. 21:953–960 (1980).PubMedGoogle Scholar
  6. 6.
    F. L. Otsuka, M. J. Welch, K. D. McElvany, R. A. Nicolotti, J. B. Fleischman, Development of a model system to evaluate methods for radiolabeling monoclonal antibodies, J. Nucl. Med. 25:1343 (1984).PubMedGoogle Scholar
  7. 7.
    F. L. Otsuka, J. B. Fleischman, and M. J. Welch, Comparative Studies using I-125- and In-111-labeled monoclonal antibodies, Nucl. Med. Biol. 13:325 (1986).Google Scholar
  8. 8.
    K. D. McElvany, K. T. Hopkins, and M. J. Welch, Comparison of Ge-68/Ga-68 generator systems for radiopharmaceut ical production, Int. J. Appl. Rad. Isotope 35:521–524 (1984).CrossRefGoogle Scholar
  9. 9.
    C. Loc’h, B. Maziere, D. Comar, A new generator for ionic gallium-68, J. Nucl. Med. 21:171 (1980).PubMedGoogle Scholar
  10. 10.
    S. J. Wagner, and M. J. Welch, Gallium-68 labeling of albumin and albumin microspheres, J. Nucl. Med. 20:428–433 (1979).PubMedGoogle Scholar
  11. 11.
    C. M. Muller-Platz, G. Kloster, G. Legier, and G. Stocklin, F-18-fluoroacetate: An agent for introducing no-carrier-added fluorine-18 into urokinase without loss of biological activity, J. Labeled Compds. Radiopharm. 19:1645–1646 (1982).Google Scholar
  12. 12.
    M. R. Kilbourn, C. S. Dence, and M. J. Welch, Reagents for fluorine-18 labeling of proteins, Sixth International Symposium on Radiopharmaceutical Chemistry, Boston, 1986, Paper 13: J. Labeled Compds. Radiopharm. (in press).Google Scholar
  13. 13.
    M. R. Kilbourn, P. A. Jerabek, and M. J. Welch, An improved O-18-water target for F-18-fluoride production, Int. J. Appl. Radiat. Isot. 36:327–328 (1985).PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1988

Authors and Affiliations

  • Michael J. Welch
    • 1
  • Michael R. Kilbourn
    • 1
  1. 1.Division of Radiation SciencesWashington University School of MedicineSt. LouisUSA

Personalised recommendations